POST Online Media Lite Edition


AstraZeneca divests some drugs to Atnahs Pharma

Christian Fernsby |
AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed dose combination).

Article continues below


Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs.

The company may also receive future sales-contingent payments of up to $40m between 2020 and 2022.

The upfront payment will be reported in AstraZeneca’s financial statements within Other Operating Income and Expense in the first quarter of 2020.

What to read next

AstraZeneca takes over Almirall
Horizon Pharma to buy Vidara Therapeutics in reverse merger
Unredacted information shows unbelievable greed of Teva Pharmaceuticals